clotrimazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	719	23593-75-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clotrimazole lotrimin rimazole locasten	An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Molecular weight: 344.84 Formula: C22H17ClN2 CLOGP: 5 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 17.82 ALOGS: -5.37 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clotrimazole
lotrimin
rimazole
locasten

An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane.

Molecular weight: 344.84
Formula: C22H17ClN2
CLOGP: 5
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 17.82
ALOGS: -5.37
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	V

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.03 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 3, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	847.15	14.16	292	15548	24084	63449098
Schizoaffective disorder	430.97	14.16	112	15728	3450	63469732
Drug level increased	249.26	14.16	119	15721	22617	63450565
Chronic sinusitis	177.58	14.16	79	15761	12764	63460418
Electrocardiogram QT prolonged	158.65	14.16	126	15714	59404	63413778
Paraesthesia oral	158.49	14.16	83	15757	19173	63454009
Procedural pain	141.49	14.16	80	15760	21489	63451693
Oral candidiasis	109.02	14.16	69	15771	22729	63450453
Vaginal flatulence	93.44	14.16	34	15806	3259	63469923
Dyspepsia	82.48	14.16	114	15726	102082	63371100
Proctitis	76.90	14.16	34	15806	5407	63467775
Vaginal discharge	68.20	14.16	37	15803	9161	63464021
Female genital tract fistula	66.25	14.16	34	15806	7525	63465657
Radiculopathy	62.08	14.16	34	15806	8577	63464605
Endocrine ophthalmopathy	61.73	14.16	17	15823	654	63472528
Vulvovaginal candidiasis	58.68	14.16	24	15816	3151	63470031
Toxic shock syndrome	57.91	14.16	17	15823	825	63472357
Swelling of eyelid	52.06	14.16	22	15818	3134	63470048
Drug interaction	50.21	14.16	148	15692	228983	63244199
Sinus rhythm	49.00	14.16	15	15825	841	63472341
Eyelid disorder	44.79	14.16	17	15823	1832	63471350
Nasal ulcer	44.58	14.16	18	15822	2286	63470896
Rectal haemorrhage	41.48	14.16	56	15784	48974	63424208
Mean cell haemoglobin increased	40.33	14.16	18	15822	2925	63470257
Eye infection toxoplasmal	39.19	14.16	10	15830	285	63472897
Vanishing bile duct syndrome	38.41	14.16	12	15828	720	63472462
Frequent bowel movements	37.70	14.16	37	15803	22985	63450197
Haematochezia	36.25	14.16	55	15785	53489	63419693
Swollen tongue	32.93	14.16	42	15798	34758	63438424
Dyslipidaemia	31.94	14.16	21	15819	7372	63465810
Therapeutic product effect decreased	31.93	14.16	5	15835	193182	63280000
Drug ineffective	31.71	14.16	398	15442	1044367	62428815
Weight decreased	31.06	14.16	144	15696	276654	63196528
Glossodynia	31.03	14.16	4	15836	178872	63294310
Pelvic pain	30.49	14.16	26	15814	13493	63459689
Therapeutic product effect incomplete	30.48	14.16	84	15756	124972	63348210
Colitis ulcerative	30.41	14.16	35	15805	26056	63447126
Candida infection	29.68	14.16	36	15804	28315	63444867
Purpura senile	28.58	14.16	9	15831	554	63472628
Rheumatoid arthritis	26.80	14.16	15	15825	253804	63219378
Tongue blistering	25.91	14.16	11	15829	1584	63471598
Drug intolerance	25.12	14.16	24	15816	308637	63164545
Vulvovaginal inflammation	25.06	14.16	9	15831	830	63472352
Malaise	24.78	14.16	183	15657	415771	63057411
Tarsal tunnel syndrome	24.33	14.16	8	15832	566	63472616
Toxicity to various agents	24.16	14.16	16	15824	247234	63225948
Colitis	23.64	14.16	43	15797	48485	63424697
Synovial cyst	23.39	14.16	20	15820	10413	63462769
Feeding disorder	22.86	14.16	22	15818	13340	63459842
Hepatic enzyme increased	22.77	14.16	11	15829	202317	63270865
Eye infection	22.70	14.16	21	15819	12124	63461058
Angiodermatitis	22.58	14.16	5	15835	76	63473106
Wound complication	22.16	14.16	13	15827	3734	63469448
Erythema	20.85	14.16	93	15747	175658	63297524
Febrile neutropenia	20.84	14.16	71	15769	118378	63354804
Skin laceration	20.84	14.16	27	15813	22681	63450501
Post viral fatigue syndrome	20.05	14.16	6	15834	311	63472871
Abdominal discomfort	19.72	14.16	31	15809	320854	63152328
Vitamin D decreased	19.70	14.16	18	15822	10224	63462958
Discomfort	18.98	14.16	9	15831	167365	63305817
Aplastic anaemia	18.77	14.16	17	15823	9552	63463630
Alopecia	18.56	14.16	35	15805	337501	63135681
Wound	18.18	14.16	9	15831	163254	63309928
Resorption bone increased	18.13	14.16	8	15832	1266	63471916
Pyrexia	18.09	14.16	188	15652	470290	63002892
Neutropenic sepsis	17.41	14.16	21	15819	16417	63456765
Vestibular disorder	17.23	14.16	8	15832	1423	63471759
Reperfusion arrhythmia	17.10	14.16	5	15835	239	63472943
Vulvovaginal discomfort	16.07	14.16	9	15831	2369	63470813
Mouth ulceration	15.77	14.16	29	15811	32955	63440227
Congenital absence of bile ducts	14.89	14.16	3	15837	28	63473154
Nausea	14.89	14.16	297	15543	854174	62619008
General physical health deterioration	14.86	14.16	17	15823	201385	63271797
Stevens-Johnson syndrome	14.62	14.16	24	15816	24926	63448256
Musculoskeletal stiffness	14.26	14.16	15	15825	184603	63288579

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pulmonary vasculitis	43.95	15.10	12	6670	587	34949662
Neuritis	38.68	15.10	12	6670	922	34949327
Respiratory symptom	31.00	15.10	12	6670	1785	34948464
Neurological symptom	26.89	15.10	14	6668	4171	34946078
Temperature regulation disorder	24.20	15.10	8	6674	754	34949495
Skin infection	21.24	15.10	15	6667	7722	34942527
Cellulitis	21.14	15.10	37	6645	52914	34897335
Hypoglycaemia neonatal	20.26	15.10	9	6673	1892	34948357
Lip haemorrhage	20.19	15.10	7	6675	763	34949486
Accident	19.22	15.10	12	6670	5035	34945214
Sleep disorder due to a general medical condition	18.85	15.10	12	6670	5209	34945040
Dermatitis atopic	18.59	15.10	12	6670	5335	34944914
Aplastic anaemia	18.21	15.10	15	6667	9701	34940548
Rash pruritic	18.12	15.10	24	6658	26917	34923332
Microtia	17.65	15.10	5	6677	280	34949969
Congenital umbilical hernia	17.33	15.10	5	6677	299	34949950
Dermatitis	16.46	15.10	14	6668	9454	34940795
Vasculitis	16.25	15.10	15	6667	11281	34938968

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Macular degeneration	180.17	13.23	75	18209	11221	79714883
Chronic sinusitis	173.11	13.23	76	18208	12950	79713154
Paraesthesia oral	151.71	13.23	80	18204	20391	79705713
Procedural pain	137.29	13.23	78	18206	23006	79703098
Oral candidiasis	102.53	13.23	71	18213	29557	79696547
Vaginal flatulence	100.39	13.23	33	18251	2542	79723562
Dyspepsia	82.96	13.23	113	18171	108574	79617530
Vaginal discharge	75.41	13.23	36	18248	7427	79718677
Female genital tract fistula	73.39	13.23	33	18251	5942	79720162
Proctitis	71.07	13.23	33	18251	6399	79719705
Vulvovaginal candidiasis	66.09	13.23	24	18260	2490	79723614
Radiculopathy	63.99	13.23	34	18250	8790	79717314
Endocrine ophthalmopathy	61.77	13.23	17	18267	711	79725393
Toxic shock syndrome	56.83	13.23	18	18266	1231	79724873
Swelling of eyelid	53.11	13.23	23	18261	3788	79722316
Nasal ulcer	47.34	13.23	18	18266	2122	79723982
Eyelid disorder	45.07	13.23	17	18267	1961	79724143
Therapeutic product effect incomplete	42.83	13.23	98	18186	141547	79584557
Haematochezia	40.05	13.23	72	18212	87573	79638531
Pulmonary vasculitis	38.95	13.23	12	18272	749	79725355
Toxicity to various agents	37.99	13.23	25	18259	421515	79304589
Aplastic anaemia	37.84	13.23	32	18252	17873	79708231
Pelvic pain	37.00	13.23	28	18256	13353	79712751
Frequent bowel movements	36.08	13.23	39	18245	29500	79696604
Mean cell haemoglobin increased	35.34	13.23	18	18266	4267	79721837
Swollen tongue	35.11	13.23	46	18238	42524	79683580
Eye infection toxoplasmal	33.83	13.23	10	18274	542	79725562
Dyslipidaemia	31.41	13.23	24	18260	11609	79714495
Rectal haemorrhage	30.27	13.23	59	18225	76241	79649863
Wound complication	30.02	13.23	17	18267	4976	79721128
Neuritis	29.13	13.23	12	18272	1746	79724358
Vanishing bile duct syndrome	29.00	13.23	12	18272	1766	79724338
Candida infection	28.02	13.23	39	18245	38175	79687929
Colitis ulcerative	27.81	13.23	37	18247	34705	79691399
Tongue blistering	27.05	13.23	11	18273	1548	79724556
Therapeutic product effect decreased	27.02	13.23	3	18281	163860	79562244
Overdose	26.60	13.23	5	18279	184201	79541903
Weight decreased	26.34	13.23	155	18129	355043	79371061
Purpura senile	25.62	13.23	8	18276	522	79725582
Rash pruritic	25.55	13.23	53	18231	71576	79654528
Tarsal tunnel syndrome	25.53	13.23	8	18276	528	79725576
Synovial cyst	25.51	13.23	20	18264	10045	79716059
Eye infection	24.56	13.23	21	18263	11899	79714205
Angiodermatitis	23.12	13.23	5	18279	74	79726030
Vitamin D decreased	21.83	13.23	18	18266	9707	79716397
Rheumatoid arthritis	20.68	13.23	11	18273	208459	79517645
Stevens-Johnson syndrome	20.26	13.23	34	18250	39132	79686972
Post viral fatigue syndrome	19.98	13.23	6	18278	343	79725761
Malaise	19.28	13.23	184	18100	489685	79236419
Feeding disorder	19.04	13.23	21	18263	16233	79709871
Gingival swelling	18.22	13.23	12	18272	4597	79721507
Systemic lupus erythematosus	18.12	13.23	3	18281	121146	79604958
Psoriasis	17.81	13.23	53	18231	89534	79636570
Respiratory symptom	17.79	13.23	12	18272	4779	79721325
Resorption bone increased	17.65	13.23	8	18276	1467	79724637
Vasculitis	17.48	13.23	25	18259	25077	79701027
Nausea	17.47	13.23	312	17972	956884	78769220
Pruritus	17.43	13.23	152	18132	394496	79331608
Vulvovaginal inflammation	17.34	13.23	6	18278	540	79725564
Urinary tract infection	17.33	13.23	115	18169	274397	79451707
Febrile neutropenia	17.22	13.23	101	18183	230898	79495206
Genital rash	16.98	13.23	7	18277	1021	79725083
Flatulence	16.89	13.23	33	18251	42691	79683413
Headache	16.85	13.23	226	18058	653546	79072558
Reperfusion arrhythmia	16.50	13.23	5	18279	295	79725809
Erythema	16.24	13.23	97	18187	223193	79502911
Pyrexia	16.02	13.23	231	18053	678478	79047626
Vulvovaginal discomfort	15.97	13.23	8	18276	1830	79724274
Lip haemorrhage	15.97	13.23	7	18277	1187	79724917
Mouth ulceration	15.60	13.23	30	18254	38364	79687740
Neurological symptom	15.16	13.23	14	18270	8769	79717335
Plicated tongue	15.06	13.23	4	18280	146	79725958
Urosepsis	15.06	13.23	24	18260	26471	79699633
Swelling face	14.99	13.23	43	18241	71169	79654935
Oral mucosal blistering	14.94	13.23	12	18272	6239	79719865
Musculoskeletal stiffness	14.91	13.23	11	18273	174997	79551107
Vulvovaginal pain	14.57	13.23	8	18276	2207	79723897
Skin disorder	14.38	13.23	27	18257	33916	79692188
Pain	14.10	13.23	233	18051	703569	79022535
Coma	13.97	13.23	3	18281	100646	79625458
Arthrodesis	13.94	13.23	8	18276	2399	79723705
Vestibular disorder	13.80	13.23	8	18276	2447	79723657
Skin ulcer	13.70	13.23	35	18249	54115	79671989
Skin laceration	13.49	13.23	24	18260	28938	79697166
Neutropenic sepsis	13.35	13.23	23	18261	27041	79699063
Kidney transplant rejection	13.34	13.23	14	18270	10232	79715872
Colitis	13.29	13.23	42	18242	73265	79652839
Hypercholesterolaemia	13.23	13.23	21	18263	23074	79703030

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A01AB18	ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment
ATC	D01AC01	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
ATC	G01AF02	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D058888	14-alpha Demethylase Inhibitors
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000891	Anti-Infective Agents, Local
MeSH PA	D000935	Antifungal Agents
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D065088	Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tinea pedis	indication	6020002	DOID:12403
Candidiasis of skin	indication	49883006
Pityriasis versicolor	indication	56454009	DOID:9060
Candidal vulvovaginitis	indication	72605008	DOID:2272
Candidiasis of mouth	indication	79740000	DOID:14262
Tinea corporis	indication	84849002
Diaper rash	indication	91487003
Tinea cruris	indication	399029005
Prevention of Oropharyngeal Candidiasis	indication
Oropharyngeal Candidiasis	indication
Paronychia	off-label use	71906005	DOID:13117
Telangiectasia disorder	contraindication	247479008
Abdominal pain - cause unknown	contraindication	314212008
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Fungal infections caused by Microsporum canis	Indication
Cats	Fungal infections caused by Trichophyton mentagrophytes	Indication
Cats	Otitis externa caused by yeast, Malassezia pachydermatis	Indication
Dogs	Fungal infections caused by Microsporum canis	Indication
Dogs	Fungal infections caused by Trichophyton mentagrophytes	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Veltrim 1% Dermatologic Cream	Elanco US Inc.	1
Otomax	Intervet Inc.	3
Mometamax Otic Suspension	Intervet Inc.	3
Tri-Otic Ointment	Med-Pharmex Inc.	3
Vetro-Max	Fougera Pharmaceuticals Inc.	3
GBC Ointment	Cronus Pharma Specialities India Private Limited	3
Mometavet	Med-Pharmex Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.4	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	5.19	DRUG MATRIX
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN		IC50	4.38	DRUG MATRIX
Nuclear receptor subfamily 1 group I member 3	Nuclear hormone receptor	Q14994	NR1I3_HUMAN	ANTAGONIST	IC50	6.16	IUPHAR
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN		Ki	6.14	DRUG MATRIX
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.35	DRUG MATRIX
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	5.39	DRUG MATRIX
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.15	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.35	DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.52	CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	7.70	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.51	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.10	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.00	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.50	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.13	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.12	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.24	DRUG MATRIX
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.43	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.05	DRUG MATRIX
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.47	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	5.78	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	5.29	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	5.68	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	5.79	DRUG MATRIX
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	5.83	DRUG MATRIX
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.27	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.35	DRUG MATRIX
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		Ki	5.11	DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.57	DRUG MATRIX
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN		IC50	7.15	CHEMBL
Nuclear receptor subfamily 1 group I member 2	Nuclear hormone receptor	O75469	NR1I2_HUMAN				WOMBAT-PK
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	5.16	DRUG MATRIX
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	4.52	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.13	DRUG MATRIX
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		Ki	5.60	DRUG MATRIX
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	5.76	DRUG MATRIX
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	4.71	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	7.80	DRUG MATRIX
Platelet-activating factor receptor	GPCR	P25105	PTAFR_HUMAN		Ki	4.65	DRUG MATRIX
Aromatase	Enzyme	P11511	CP19A_HUMAN		IC50	8.74	CHEMBL
Cysteinyl leukotriene receptor 1	GPCR	Q9Y271	CLTR1_HUMAN		Ki	4.78	CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	4.16	DRUG MATRIX
Vasopressin V2 receptor	GPCR	P30518	V2R_HUMAN		IC50	5.60	CHEMBL
Substance-P receptor	GPCR	P25103	NK1R_HUMAN		Ki	5.06	DRUG MATRIX
Steroid 17-alpha-hydroxylase/17,20 lyase	Enzyme	P05093	CP17A_HUMAN		IC50	7.09	WOMBAT-PK
Potassium voltage-gated channel subfamily A member 3	Ion channel	P22001	KCNA3_HUMAN		IC50	5.22	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	7.80	DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	4.50	DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	4.18	DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	7.85	DRUG MATRIX
Bile acid receptor	Nuclear hormone receptor	Q96RI1	NR1H4_HUMAN		IC50	5.49	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme	Q16850	CP51A_HUMAN		IC50	6.89	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.92	CHEMBL
Substance-K receptor	GPCR	P21452	NK2R_HUMAN		Ki	5.47	DRUG MATRIX
Transient receptor potential cation channel subfamily M member 2	Ion channel	O94759	TRPM2_HUMAN		IC50	5.52	CHEMBL
C-C chemokine receptor type 4	GPCR	P51679	CCR4_HUMAN		IC50	5.80	CHEMBL
C-X-C chemokine receptor type 1	GPCR	P25024	CXCR1_HUMAN		IC50	5.70	CHEMBL
Transitional endoplasmic reticulum ATPase	Enzyme	P55072	TERA_HUMAN		IC50	5.85	CHEMBL
Malate dehydrogenase cytoplasmic	Enzyme	P40925	MDHC_HUMAN		IC50	4.46	CHEMBL
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase	Enzyme	Q9UNU6	CP8B1_HUMAN		IC50	6.10	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	5.17	WOMBAT-PK
Lanosterol 14-alpha demethylase	Enzyme		CP51_CANAL	INHIBITOR			CHEMBL	CHEMBL
Beta-lactamase	Enzyme		AMPC_ECOLI		IC50	4.70	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.11	DRUG MATRIX
5-hydroxytryptamine receptor 1B	GPCR		5HT1B_RAT		Ki	4.91	DRUG MATRIX
Cysteinyl leukotriene receptor 1	GPCR		CLTR1_CAVPO		Ki	4.78	DRUG MATRIX
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	4.58	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	4.75	CHEMBL
Lanosterol 14-alpha demethylase	Enzyme		CP51_MYCTU		Kd	6.70	CHEMBL
14-alpha sterol demethylase Cyp51A	Enzyme		Q4WNT5_ASPFU		Kd	5.32	CHEMBL
14-alpha sterol demethylase	Enzyme		Q96W81_ASPFM		Kd	6.99	CHEMBL
Indoleamine 2,3-dioxygenase 2	Enzyme		I23O2_MOUSE		IC50	5.23	CHEMBL
Mycocyclosin synthase	Enzyme		CP121_MYCTU		Kd	7.14	CHEMBL
Putative cytochrome P450 130	Enzyme		CP130_MYCTU		Kd	4.88	CHEMBL
Alpha-chymotrypsin	Enzyme		CTRA_BOVIN		IC50	4.07	CHEMBL
Indoleamine 2,3-dioxygenase 1	Enzyme		I23O1_MOUSE		IC50	4.29	CHEMBL
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Enzyme		AT2A1_RABIT		Ki	4.46	CHEMBL

External reference:

ID	Source
4018265	VUID
N0000146595	NUI
D00282	KEGG_DRUG
202859	RXNORM
4018265	VANDF
C0009074	UMLSCUI
CHEBI:3764	CHEBI
CL6	PDB_CHEM_ID
CHEMBL104	ChEMBL_ID
DB00257	DRUGBANK_ID
D003022	MESH_DESCRIPTOR_UI
2812	PUBCHEM_CID
2330	IUPHAR_LIGAND_ID
2912	INN_ID
G07GZ97H65	UNII
1284	MMSL
4482	MMSL
d01236	MMSL
002916	NDDF
387325003	SNOMEDCT_US
5797005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-4146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0054-8146	LOZENGE	10 mg	ORAL	ANDA	14 sections
Lotrisone	HUMAN PRESCRIPTION DRUG LABEL	2	0085-0924	CREAM	10 mg	TOPICAL	NDA	26 sections
Good Sense Athletes Footantifungal	HUMAN OTC DRUG LABEL	1	0113-0857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Clotrimazole	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0133	CREAM	10 mg	TOPICAL	ANDA	20 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0258	CREAM	10 mg	TOPICAL	ANDA	27 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0168-0370	LOTION	10 mg	TOPICAL	ANDA	20 sections
Fungicure Liquid Gel	HUMAN OTC DRUG LABEL	1	0295-1363	LIQUID	10 mg	TOPICAL	OTC monograph final	9 sections
Fungicure Manicure Pedicure Anti Fungal	HUMAN OTC DRUG LABEL	1	0295-6307	LIQUID	1 mg	TOPICAL	OTC monograph final	10 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
WALGREENS CLOTRIMAZOLE	HUMAN OTC DRUG LABEL	1	0363-1299	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
athletes foot	HUMAN OTC DRUG LABEL	1	0363-1857	CREAM	1 g	TOPICAL	OTC monograph final	13 sections
Walgreens Clotrimazole 3	HUMAN OTC DRUG LABEL	1	0363-2062	CREAM	2 g	VAGINAL	NDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-2105	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Ringworm	HUMAN OTC DRUG LABEL	1	0363-2107	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Ringworm	HUMAN OTC DRUG LABEL	1	0363-2107	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Walgreens Jock Itch	HUMAN OTC DRUG LABEL	1	0363-2109	CREAM	10 mg	TOPICAL	OTC MONOGRAPH FINAL	14 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0363-3492	LIQUID	1 mg	TOPICAL	OTC monograph final	8 sections
Walgreens Clotrimazole Antifungal	HUMAN OTC DRUG LABEL	1	0363-7412	CREAM	1 g	TOPICAL	OTC monograph final	11 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0472-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0472-0220	CREAM	10 mg	VAGINAL	ANDA	16 sections
ClotrimazoleAntifungal	HUMAN OTC DRUG LABEL	1	0472-0350	CREAM	10 mg	TOPICAL	OTC monograph final	13 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole and Betamethasone Dipropionate	HUMAN PRESCRIPTION DRUG LABEL	2	0472-0379	CREAM	10 mg	TOPICAL	ANDA	24 sections
Clotrimazole	HUMAN OTC DRUG LABEL	1	0536-1181	SOLUTION	1 g	TOPICAL	OTC monograph final	13 sections
Rugby Clotrimazole Antifungal Cream	HUMAN OTC DRUG LABEL	1	0536-1265	CREAM	1 g	TOPICAL	OTC monograph final	12 sections
Rugby Clotrimazole Antifungal Cream	HUMAN OTC DRUG LABEL	1	0536-1265	CREAM	1 g	TOPICAL	OTC monograph final	12 sections